Relay Therapeutics, Inc. (RLAY) — 8-K Filings

8-K Filings (12)

• Relay Therapeutics Appoints New Chief Medical Officer — Jun 11, 2025 Risk: medium
  Relay Therapeutics, Inc. announced on June 11, 2025, that its Board of Directors appointed Dr. Sarah Michaels as Chief Medical Officer, effective June 8, 2025.
• Relay Therapeutics Files 8-K on Shareholder Votes — Jun 6, 2025 Risk: low
  Relay Therapeutics, Inc. filed an 8-K on June 6, 2025, to report on matters submitted to a vote of its security holders. The filing details the company's princi
• Relay Therapeutics Reports Material Agreements — Jun 4, 2025 Risk: medium
  On June 3, 2025, Relay Therapeutics, Inc. reported the entry into a material definitive agreement and the termination of a material definitive agreement. The co
• Relay Therapeutics Files 8-K — Jan 13, 2025 Risk: low
  On January 13, 2025, Relay Therapeutics, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and the submission of Financial Statem
• Relay Therapeutics Files 8-K — Dec 11, 2024 Risk: low
  On December 11, 2024, Relay Therapeutics, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events and
• Relay Therapeutics Files 8-K for Material Definitive Agreement — Sep 11, 2024 Risk: medium
  On September 9, 2024, Relay Therapeutics, Inc. entered into a material definitive agreement. The company, headquartered in Cambridge, MA, filed an 8-K report wi
• Relay Therapeutics Files 8-K — Sep 9, 2024 Risk: low
  On September 9, 2024, Relay Therapeutics, Inc. filed an 8-K report. The filing primarily concerns Regulation FD disclosures and other events, along with financi
• Relay Therapeutics Terminates Material Definitive Agreement — Jul 16, 2024 Risk: medium
  Relay Therapeutics, Inc. announced on July 11, 2024, the termination of a material definitive agreement. The company, incorporated in Delaware with its principa
• Relay Therapeutics to be Acquired by G42 Investments for $1.1B — Jun 6, 2024 Risk: medium
  Relay Therapeutics, Inc. announced on June 5, 2024, that it has entered into a definitive agreement to be acquired by G42 Investments for $15.00 per share in ca
• Relay Therapeutics Files 8-K on Security Holder Vote Matters — Jun 3, 2024 Risk: low
  Relay Therapeutics, Inc. filed an 8-K on June 3, 2024, to report on the submission of matters to a vote of its security holders. The filing does not contain spe
• Relay Therapeutics Files 8-K on Financial Condition — Feb 22, 2024 Risk: low
  Relay Therapeutics, Inc. filed an 8-K on February 22, 2024, to report on its results of operations and financial condition. The filing, under SEC File Number 00
• Relay Therapeutics Enters Material Agreement, Sells Equity — Jan 8, 2024
  Relay Therapeutics, Inc. filed an 8-K on January 8, 2024, indicating an entry into a material definitive agreement and unregistered sales of equity securities.

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX